Document:

EMPLOYMENT AGREEMENT WITH MARTIN D. WILLIAMS

 
Exhibit 10.4

 
March 31, 2003 
 
EMPLOYMENT AGREEMENT 
 
Martin D. Williams 
125 Coolidge Avenue #204 
Watertown, MA 02472

 
Dear Martin: 
 
This letter will confirm our offer to you of employment with
Genome Therapeutics Corp. (the “Company”), under the terms and conditions that follow: 
 
1.    Position and Duties. Effective July, 2001, you will be employed by the Company, on a full-time basis as its Senior Vice President, Business Development & Marketing-
Infectious Disease. You agree to perform the duties of your position and such other duties as may reasonably be assigned to you from time to time. You also agree that, while employed by the Company, you will devote your full business time and your
best efforts, skill and knowledge exclusively to the advancement of the business and interests of the Company and its subsidiaries and to the discharge of your duties and responsibilities for them. You warrant that you are free to enter into and
fully perform this agreement and are not subject to any employment, confidentiality, non-competition or other agreement which conflicts with this agreement. 
 
2.    Compensation and Benefits. During your employment, as compensation for all services performed by you for
the Company and its subsidiaries, the Company will provide you the following pay and benefits: 
 
a.    Base Salary. The Company will pay you a base salary of $220,000 per annum payable in accordance with the regular payroll practices of the Company and subject to
increase from time to time by the Board of Directors of the Company (the “Board”) in its discretion (such base salary as in effect from time to time, the “Base Salary”). Your base salary will be increased to $250,000 on your
first anniversary date provided that you have achieved mutually agreed upon performance objective(s). 
 
b.    Hiring Bonus: In lieu of a signing bonus and subject to Compensation Committee approval, you will be
granted stock options equivalent to $30,000. The number of options to be granted will be determined at date of hire and will be based on 70% discount of the fair market value of the Company stock price at date of approval and vest in two
installments. Options equivalent to $15,000 will vest upon grant with the balance to 
 

1 

 
vest 18 months from date
employment. In addition you will receive a cash-signing bonus of $30,000 payable on a quarterly basis. 
 
c.    Bonus Compensation. During your employment, pursuant to the Company’s Management Incentive Plan, you
will be considered annually for a bonus of up to thirty (30%) of your Base Salary. For fiscal year 2001, your target bonus shall be pro-rated for the part of the fiscal year for which you were employed by the Company. It is anticipated that the
Company’s fiscal year will be changed to a December 31 year-end. Bonus awards will be determined by the Board, based on your performance and that of the Company against goals established annually by the Board after consultation with you.
Subject to Board approval, half of any annual bonus will be paid in cash and half will be paid in options on the Company’s common stock. 
 
d.    Stock Options. You will be nominated for stock option award equal to 100,000 shares of combined ISO and
non-qualified options, as determined by the Compensation Committee, which vest in equal annual installments over a four (4) year period, on your anniversary date, and of which 50,000 options may vest, subject to Compensation Committee approval, on
an accelerated basis upon achievement of the goals noted below. The strike price for this option grant will be the fair market value of the Company stock at date of approval. The terms of these options are governed by the Company’s option plans
and stock option agreements between the Company and you. 
 

	 Stock Vesting Performance Goals
	 	 Options Eligible for Accelerated Vesting

	
	 IND filing of an acquired or in-licensed product resulting from your direct
efforts
	 	 25,000

	
	 Date of First Sale of an acquired or in-licensed product resulting from your direct
efforts
	 	 25,000

 
e.    Participation in Employee Benefit Plans. You will be entitled to participate in all employee benefit plans from time to time in effect on the same basis as other executive employees of the Company,
except to the extent such plans are duplicative of benefits otherwise provided to you under this agreement. Your participation will be subject to the terms of the applicable plan documents and applicable Company policies. 
 
f.    Vacations and other Benefits:
You will be entitled to four (4) weeks of vacation per year, in addition to holidays observed by the Company. Vacation may be taken at such times and intervals as you shall determine, subject to the business needs of the Company. In addition,
the Company shall provide you with a cellular telephone and related service plan. 
 
g.    Confidential Information and Restricted Activities. You acknowledge that, in consideration for your employment with the Company, you have 
 

2 

 
agreed to and executed a
joinder dated July 30, 2001 to Genome Therapeutics’ Intellectual Property Policy, including Appendix I thereof (“Invention, Assignment, Non-Disclosure and Covenant Not To Compete”), which imposes certain non-competition,
non-solicitation and non-disclosure restrictions on you (such joinder referred to hereinafter as the “Intellectual Property and Non-Compete Agreement”). 
 
3.    Termination of Employment; Severance. Your employment under this agreement
shall continue until one party delivers to the other party a written notice of termination setting forth the reason, if any, for the termination. If you terminate your employment without Good Reason (as defined below), you will give the Company
reasonable written notice. 
 
a.    In the event of termination of your employment by the Company other than for Cause (as defined below) or your termination of employment for Good Reason (as defined below), the Company will: (i) continue to
pay you your Base Salary and provide you with the benefits set forth in paragraph 2.e. hereof for the lesser of (x) a period of nine (9) months from the date of termination or (y) such period of time that it takes you to find comparable employment;
(ii) pay you on the date of termination any Base Salary earned but not paid through the date of termination; and (iii) pay you any bonus to which you are entitled in accordance with paragraph 2.c. above, prorated to the date of termination and
payable at the time such bonuses are payable to Company executives generally. All severance payments will be payable in accordance with the normal payroll practices of the Company. 
 
b.    In the event of termination of your employment by the Company for Cause or
termination by you other than for Good Reason, the Company will have no further obligations to you other than paying you any Base Salary earned but not paid through the date of termination. 
 
c.    If within two years of a Change of
Control (as defined in Exhibit A hereto) of the Company, (i) you are terminated other than for Cause, or (ii) you terminate your employment with the surviving company due to the fact that (a) the surviving company takes any action that results in a
material diminution in your position, authority or duties as such position, authority or duties existed immediately prior to the Change of Control or (b) the surviving company takes any action that would require you to have your principal place of
work changed to any location outside a thirty-five (35) mile radius of the City of Boston, then, in the case of either (i) or (ii), the Company will continue to pay your Base Salary (as in effect at the time of your termination) and provide you with
the benefits set forth in paragraph 2.e. above for a period of twelve (12) months from the date of termination. The Company will also pay you on the date of termination any Base Salary earned but not paid through the date of termination. All
severance payments will be payable in accordance with the normal payroll practices of the Company. If you are eligible for severance payments under this paragraph upon termination, then the provisions of paragraph 3.a. above shall not apply to such
termination. In addition, your remaining unvested options and non-exercisable restricted shares will immediately fully vest and become exercisable for a period equal to the lesser of two years from the termination date 
 

3 

 
or until the final exercise
date of the options as determined in the applicable stock option agreement between yourself and the Company 
 
d.    For purposes of this agreement, “Cause” shall mean: (i) your material failure to perform (other than
by reason of disability), or material negligence in the performance of, your duties and responsibilities to the Company or any of its subsidiaries; (ii) your material breach of this agreement or any other agreement between you and the Company or any
of its subsidiaries; (iii) the commission of a felony or other crime involving an act of moral turpitude; or (iv) a material act of dishonesty or breach of trust on your part resulting or intended to result, directly or indirectly, in a personal
gain or enrichment at the expense of the Company. 
 
e.    For purposes of this agreement, “Good Reason” shall mean: (i) any action by the Company that results in a material diminution in your position, authority or duties with the Company, excluding any
isolated, insubstantial or inadvertent action not taken in bad faith and which is promptly remedied by the Company; (ii) material failure of the Company to provide you compensation and benefits in accordance with the terms of paragraph 2 of this
agreement for more than ten business days after notice from you specifying in reasonable detail the nature of the failure or (iii) a Change of Control. 
 
f.    This agreement shall automatically terminate in the event of your death during employment. In the event you
become disabled during employment and, as a result, are unable, in the reasonable judgment of the Board, to continue to perform substantially all of your duties and responsibilities under this agreement, the Company will continue to pay you your
Base Salary and to provide you benefits in accordance with paragraph 2.e. above, to the extent permitted by plan terms, for up to twenty-six (26) weeks of disability during any period of three hundred and sixty-five (365) consecutive calendar days.
The obligations of the Company to make payments to you due to disability pursuant to this paragraph 3.f. shall be reduced by the amount of any payments you receive pursuant to the Company’s disability insurance policy. If you are, in the
reasonable judgment of the Board, unable to return to work after twenty-six (26) weeks of disability, the Company may terminate your employment, upon notice to you 
 
4.    Miscellaneous. This agreement sets forth the entire agreement between you
and the Company and replaces all prior and contemporaneous communications, agreements and understandings, written or oral, with respect to the terms and conditions of your employment, including, without limitation, the letter agreement between you
and the Company dated July 23, 2001; provided, however, that you and the Company acknowledge and agree that the Intellectual Property and Non-Competition Agreement shall remain in full force and effect. This agreement may not be
modified or amended, and no breach shall be deemed to be waived, unless agreed to in writing by you and an expressly authorized representative of the Board. This agreement may be executed in two or more counterparts, each of which shall be an
original and all of which together shall constitute one and the same instrument. This is a Massachusetts contract and shall be governed and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to the conflict of
laws principles thereof. All payments made hereunder shall be net of any tax or 
 

4 

 
other amount required to be
withheld by the Company by law. Neither you nor the Company may make any assignment of this agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may
assign its rights and obligations under this agreement without your consent to one of its subsidiaries or to any Person that acquires substantially all the assets of the Company, by means of a merger or otherwise. Your obligations to the Company
under the Intellectual Property and Non-Competition Agreement shall survive the termination of this agreement. 
 
5.    Notices. Any notices provided for in this agreement shall be in writing and shall be effective when
delivered in person or deposited in the United States mail, postage prepaid, and addressed to you at your last known address on the books of the Company or, in the case of the Company, to it at its principal place of business, attention of the Chief
Executive Officer, or to such other address as either party may specify by notice to the other actually received. 
 
6.    Binding Effect. This agreement shall be binding upon and inure to the benefit of your heirs and
representatives and the successors and assigns of the Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, reorganization, consolidation, acquisition of property or stock, liquidation, or otherwise) to
all or a significant portion of its assets, by agreement in form and substance satisfactory to you, expressly to assume and agree to perform this agreement in the same manner and to the same extent that the Company would be required to perform this
agreement if no such succession had taken place. Regardless of whether such agreement is executed, this agreement shall be binding upon any successor of the Company in accordance with the operation of law and such successor shall be deemed the
“Company” for purposes of this agreement. 
 
At the time you sign and return it this letter will take effect as a binding agreement between you and the Company on the basis set forth above. The enclosed copy is for your records. 
 

	 Sincerely yours,
	 	 	 	 Accepted and Agreed:

	
	 /s/    STEVEN M.
RAUSCHER        

	 	 	 	 /s/    MARTIN
WILLIAMS        

	 Steven M. Rauscher
 President andChief Executive Officer
	 	 	 	 Martin Williams
  
 Date:    March 31,
2003                                

 

5 

 
Definition
of Change of Control 
 
A “Change of
Control” shall be deemed to have occurred if and when: (i) the Company executes an agreement of acquisition, merger, or consolidation which contemplates that after the effective date provided for in the agreement, all or substantially all of
the business and/or assets of the Company shall be controlled by another corporation or other entity; provided, however, for purposes of this clause (i) that (A) if such an agreement requires as a condition precedent approval by the
Company’s shareholders of the agreement or transaction, a Change of Control shall not be deemed to have taken place unless and until such approval is secured and, (B) if immediately after such effective date the voting shareholders of such
other corporation or entity shall be substantially the same as the voting shareholders of the Company immediately prior to such effective date, the execution of such agreement shall not, by itself, constitute a “Change of Control;” (ii)
any “person” (as such term is used in Sections 13(d) or 14(d)(2) of the Securities Exchange Act of 1934) becomes the beneficial owner, directly or indirectly, of securities of the Company that represent 35% or more of the votes that could
then be cast in an election for members of the Company’s Board; or (iii) during any period of 24 consecutive months, commencing after the effective date of this agreement, individuals who at the beginning of such 24-month period were directors
of the Company shall cease to constitute at least a majority of the Company’s Board, unless the election of each director who was not a director at the beginning of such period has been approved in advance by directors representing at least two
thirds of (A) the directors then in office who were directors at the beginning of the 24-month period, or (B) the directors specified in clause (A) plus directors whose election has been so approved by directors specified in clause (A).

 

6AGREEMENT OF SUBSTITUTION AND AMENDMENT OF COMMON STOCKS RIGHTS AGREEMENT

 
Exhibit 10.1

 
AGREEMENT OF SUBSTITUTION AND AMENDMENT OF

COMMON STOCK RIGHTS AGREEMENT 
 
This Agreement of Substitution and Amendment is entered into as of February 14, 2003, by and between
Millipore Corporation, a Massachusetts corporation (the “Company”) and American Stock Transfer and Trust Company, a New York banking corporation (“AST”). 
 
RECITALS 
 

	A.	 	On April 16, 1998 the Company entered into a Common Stock Rights Agreement (the “Rights Agreement”) with The First National Bank of Boston (subsequently
Equiserve Trust Company, N.A.) (the “Predecessor Agent”) as rights agent. 

 

	B.	 	The Company wishes to remove the Predecessor Agent and substitute AST as rights agent pursuant to Section 21 of the Rights Agreement. 

 

	C.	 	The Company has given the Predecessor Agent notice of removal of the Predecessor Agent as rights agent. 

 
AGREEMENT 
 
NOW THEREFORE, in consideration of the foregoing and of other consideration, the sufficiency of which
is hereby acknowledged, the parties agree as follows: 
 

	1.	 	Section 21 of the Rights Agreement is hereby amended to provide that any successor rights agent shall, at the time of its appointment as rights agent, have a
combined capital and surplus of at least $10 million, rather than $50 million. 

 

	2.	 	The Company hereby appoints AST as rights agent pursuant to Section 21 of the Rights Agreement, to serve in that capacity for the consideration and subject to all of
the terms and conditions of the Rights Agreement. 

 

	3.	 	AST hereby accepts the appointment as rights agent pursuant to Section 21 of the Rights Agreement and agrees to serve in that capacity for the consideration and
subject to all of the terms and conditions of the Rights Agreement. 

 

	4.	 	From and after the effective date hereof, each and every reference in the Rights Agreement to a “Rights Agent” shall be deemed to be a reference to AST.

 

	5.	 	Section 26 of the Rights Agreement is amended to provide that notices or demands shall be addressed as follows (until another address is filed):

 

	 If to the Company:
	  	 MILLIPORE CORPORATION

	 	  	 290 Concord Road

	 	  	 Billerica, MA 01821-3405

	 	  	 Attention: General Counsel

	
	 with a copy to:
	  	 David B. Walek

	 	  	 Ropes & Gray

	 	  	 One International Place

	 	  	 Boston, MA 02110-2624

	
	 If to AST:
	  	 American Stock Transfer & Trust Company

	 	  	 59 Maiden Lane

	 	  	 New York, NY 10038

	 	  	 Attention: Corporate Trust Department

 

	6.	 	Except as expressly modified herein, the Right Agreement shall remain in full force and effect. 

 

	7.	 	This Agreement of Substitution and Amendment may be executed in one or more counterparts, each of which shall together constitute one and the same document.

 
IN WITNESS WHEREOF, the
parties have caused this Agreement to be duly executed as of the date first above written: 
 

	 MILLIPORE CORPORATION

	
	 By:
	 	 /s/    JEFFREY
RUDIN        

	 	 	 Jeffrey Rudin

 

	 AMERICAN STOCK TRANSFER & TRUST
COMPANY

	
	 By:
	 	 /s/    HERBERT J.
LEMMER        

	 	 	 HERBERT J. LEMMER
 VICE PRESIDENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00051-of-00352.parquet"}]]